Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Hyperhidrosis Treatment Market

Hyperhidrosis Treatment Market Trends

Report ID: GMI9862
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Hyperhidrosis Treatment Market Trends

The rising prevalence of hyperhidrosis is a critical factor contributing to the market's growth. Increased stress levels, changing lifestyles, and higher incidence of associated conditions such as obesity and diabetes are contributing to a higher number of hyperhidrosis cases.
For instance, according to National Institutes of Health (NIH), the worldwide prevalence of hyperhidrosis was reported to be ranging from 0.072% to 38% of population. Thus, as the prevalence of hyperhidrosis continues to grow, the need for effective treatment options rises, thereby expanding the market.
Additionally, minimally invasive procedures like botulinum toxin injections (e.g., Botox) and microwave thermolysis are gaining popularity due to their effectiveness and relatively low risk. Patients increasingly prefer these options over traditional surgical interventions, which can be more invasive and have longer recovery periods. This shift in preference is further bolstering the growth of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global hyperhidrosis treatment industry was valued at USD 671.6 million in 2023 and is anticipated to register 5.3% CAGR between 2024 and 2032 due to the increasing prevalence of hyperhidrosis and growing awareness and diagnosis rates.

The axillary segment in the market held 44.8% revenue share in 2023 due to high prevalence of axillary hyperhidrosis and wide range of effective treatment options that are readily available and widely accepted by both patients and healthcare providers.

North America hyperhidrosis treatment market size is expected to record 5% CAGR between 2024 and 2032 due to the presence of advanced healthcare infrastructure, technological advancements and ongoing research initiatives.

AbbVie Inc., Avanor Healthcare Ltd., Brickell Biotech Inc., Dermadry Laboratories Inc., Dermavant Sciences Inc., Hugel, Inc., Eirion Therapeutics, Inc, Eli Lilly and Company, Intas Pharmaceuticals Ltd and Kaken Pharmaceutical Co., Ltd., among others.